Dipeptidyl Peptidase 4

"Dipeptidyl Peptidase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A serine protease that catalyses the release of an N-terminal dipeptide. Several biologically-active peptides have been identified as dipeptidyl peptidase 4 substrates including INCRETINS; NEUROPEPTIDES; and CHEMOKINES. The protein is also found bound to ADENOSINE DEAMINASE on the T-CELL surface and is believed to play a role in T-cell activation.

Descriptor ID	D018819
MeSH Number(s)	D08.811.277.656.350.350.126 D08.811.277.656.959.250 D23.050.301.264.894.160 D23.101.100.894.160
Concept/Terms	Dipeptidyl Peptidase 4 Dipeptidyl Peptidase 4 CD26 Antigen Antigen, CD26 Antigens, CD26 Adenosine Deaminase Complexing Protein 2 Dipeptidyl-Peptidase IV Dipeptidyl Peptidase IV CD26 Antigens

Below are MeSH descriptors whose meaning is more general than "Dipeptidyl Peptidase 4".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Hydrolases [D08.811.277]
Peptide Hydrolases [D08.811.277.656]
Exopeptidases [D08.811.277.656.350]
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases [D08.811.277.656.350.350]
Dipeptidyl Peptidase 4 [D08.811.277.656.350.350.126]
Serine Proteases [D08.811.277.656.959]
Dipeptidyl Peptidase 4 [D08.811.277.656.959.250]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Antigens, Differentiation [D23.050.301.264]
Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
Dipeptidyl Peptidase 4 [D23.050.301.264.894.160]
Biomarkers [D23.101]
Antigens, Differentiation [D23.101.100]
Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
Dipeptidyl Peptidase 4 [D23.101.100.894.160]

Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl Peptidase 4".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dipeptidyl Peptidase 4" by people in this website by year, and whether "Dipeptidyl Peptidase 4" was a major or minor topic of these publications.

Bar chart showing 11 publications over 9 distinct years, with a maximum of 2 publications in 2017 and 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2009	0	1	1
2010	0	1	1
2011	1	0	1
2015	1	0	1
2016	0	1	1
2017	2	0	2
2018	1	0	1
2019	1	0	1
2020	1	1	2

Below are the most recent publications written about "Dipeptidyl Peptidase 4" by people in Profiles.

Sachinidis A, Nikolic D, Stoian AP, Papanas N, Tarar O, Rizvi AA, Rizzo M. Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020 10; 111:154343.

View in: PubMed
Nelson MH, Knochelmann HM, Bailey SR, Huff LW, Bowers JS, Majchrzak-Kuligowska K, Wyatt MM, Rubinstein MP, Mehrotra S, Nishimura MI, Armeson KE, Giresi PG, Zilliox MJ, Broxmeyer HE, Paulos CM. Identification of human CD4+ T cell populations with distinct antitumor activity. Sci Adv. 2020 07; 6(27).

View in: PubMed
Elmansi AM, Awad ME, Eisa NH, Kondrikov D, Hussein KA, Aguilar-Pérez A, Herberg S, Periyasamy-Thandavan S, Fulzele S, Hamrick MW, McGee-Lawrence ME, Isales CM, Volkman BF, Hill WD. What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands. Pharmacol Ther. 2019 06; 198:90-108.

View in: PubMed
Al-Awar A, Almási N, Szabó R, Takacs I, Murlasits Z, Szucs G, Török S, Pósa A, Varga C, Kupai K. Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model. Int J Mol Sci. 2018 Oct 18; 19(10).

View in: PubMed
Bailey SR, Nelson MH, Majchrzak K, Bowers JS, Wyatt MM, Smith AS, Neal LR, Shirai K, Carpenito C, June CH, Zilliox MJ, Paulos CM. Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nat Commun. 2017 12 06; 8(1):1961.

View in: PubMed
Carbone LD, Bužková P, Fink HA, Robbins JA, Bethel M, Isales CM, Hill WD. Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study. Osteoporos Int. 2017 05; 28(5):1631-1640.

View in: PubMed
Williams RD, Denlinger CE. Single-agent management of diabetes and ischemia reperfusion injury. J Thorac Cardiovasc Surg. 2017 03; 153(3):711-712.

View in: PubMed
Meissner EG, Decalf J, Casrouge A, Masur H, Kottilil S, Albert ML, Duffy D. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015; 10(7):e0133236.

View in: PubMed
Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2011 Aug; 58(2):157-66.

View in: PubMed
Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec; 213(2):429-35.

View in: PubMed

People

Explore

Similar Concepts

Top Journals